Cara Therapeutics announces effective date of 1-for-12 reverse stock split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 27 2024
0mins
Should l Buy ?
Reverse Stock Split Announcement: Cara Therapeutics will implement a 1-for-12 reverse stock split effective December 30, 2024, reducing its authorized shares from 200 million to approximately 16.67 million.
Compliance with Nasdaq Requirements: The reverse stock split aims to help the company meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market, with trading under the symbol "CARA" continuing post-split.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
